Alyea Therapeutics to Attend ArcStone-Kingswood Growth Summit in Toronto

Alyea Therapeutics, a biotechnology company focused on developing non-opioid solutions for chronic pain, is set to participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026. The summit, held at the Sheraton Centre Toronto Hotel, will bring together growth issuers and a curated group of investors, family offices, institutional investors, and capital market professionals for a full day of company presentations, networking, and one-on-one meetings.

Amol Soin, MD, CEO of Alyea Therapeutics, will represent the company at the event. Soin stated, "We are excited to participate in the ArcStone-Kingswood Growth Summit and share Alyea Therapeutics' vision for developing innovative, non-opioid therapies for patients with significant unmet needs in pain management. With a growing pipeline of differentiated programs and a strategy focused on advancing clinically meaningful therapies, we believe Alyea is well positioned to create value for patients, physicians, and shareholders."

Alyea Therapeutics is a wholly owned subsidiary of AIFC Corporation (NASDAQ: AIFC). The company's lead investigational program is low-dose naltrexone (LDN) for Complex Regional Pain Syndrome (CRPS), which has received FDA orphan drug designation and is advancing through clinical development. Additionally, Alyea is developing the Alyea Clear Patch, a topical pain-relief technology designed for targeted, non-invasive treatment.

The ArcStone-Kingswood Growth Summit will feature a curated program of one-on-one meetings connecting investors with appropriate projects, alongside keynote presentations, panel discussions, and conversations on industry developments. Interested investors can register for a free pass to the event.

ArcStone Securities and Investments Corp., a diversified financial services firm with offices in New York and Toronto, is hosting the summit. The company specializes in providing bespoke solutions to mid-market companies worldwide, with a particular focus on cross-border transactions between Canada and the United States. ArcStone's partnership with Kingswood US enhances its ability to offer a full spectrum of financial services to clients.

Kingswood US is a mid-market investment bank with a strong retail equity capital markets franchise and a deep-rooted investment bank. The firm is dedicated to providing comprehensive financial services, including investment banking, wealth management, and capital raising, to clients across the United States.

Alyea Therapeutics' participation in the ArcStone-Kingswood Growth Summit underscores the company's commitment to advancing its innovative pain management solutions and engaging with key stakeholders in the industry.